JPMorgan lowered the firm’s price target on Roche (RHHBY) to CHF 325 from CHF 350 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Xencor reports receipt of notice of termination of license agreement from Roche
- H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
- Genentech announces persevERA Breast Cancer study did not meet primary endpoint
- Controversial Prasad leaving FDA, NYT reports
- Roche Chairman says diagnostics division exposed to tariffs, Reuters says